Mian Chen

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Neutralising autoantibodies against IL-10 and HLA-DRB1*01:03 in paediatric patients with inflammatory bowel disease.

Neutralising autoantibodies against IL-10 and HLA-DRB1*01:03 in paediatric patients with inflammatory bowel disease.

Journal: Gut

Published: May 05, 2026

BeadWatch: Automated Longitudinal Quality Control Monitoring for Luminex Bead-Based Immunoassays in Histocompatibility Laboratories.

BeadWatch: Automated Longitudinal Quality Control Monitoring for Luminex Bead-Based Immunoassays in Histocompatibility Laboratories.

Journal: HLA

Published: April 02, 2026

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.

Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.

Journal: Annals of translational medicine

Published: November 26, 2020

Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.

Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.

Journal: OncoTargets and therapy

Published: October 10, 2020

Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients.

Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients.

Journal: Frontiers in immunology

Published: October 04, 2020

Withdrawn: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.

Withdrawn: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.

Journal: British journal of clinical pharmacology

Published: May 05, 2020

Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.

Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.

Journal: Bioorganic & medicinal chemistry

Published: April 15, 2020

Next-Generation Sequencing Characterizes the Landscape of Somatic Mutations and Pathways in Metastatic Bile Tract Carcinoma.

Next-Generation Sequencing Characterizes the Landscape of Somatic Mutations and Pathways in Metastatic Bile Tract Carcinoma.

Journal: Journal of oncology

Published: March 09, 2020

Towards uniformity in the definition of acceptable mismatches for highly sensitized patients.

Towards uniformity in the definition of acceptable mismatches for highly sensitized patients.

Journal: HLA

Published: March 22, 2019

Distinct HLA associations of LGI1 and CASPR2-antibody diseases.

Distinct HLA associations of LGI1 and CASPR2-antibody diseases.

Journal: Brain : a journal of neurology

Published: September 08, 2017

De novo donor-specific HLA antibodies after combined intestinal and vascularized composite allotransplantation - a retrospective study.

De novo donor-specific HLA antibodies after combined intestinal and vascularized composite allotransplantation - a retrospective study.

Journal: Transplant international : official journal of the European Society for Organ Transplantation

Published: June 06, 2017

Application of Operational Tolerance Signatures Are Limited by Variability and Type of Immunosuppression in Renal Transplant Recipients: A Cross-Sectional Study.

Application of Operational Tolerance Signatures Are Limited by Variability and Type of Immunosuppression in Renal Transplant Recipients: A Cross-Sectional Study.

Journal: Transplantation direct

Published: October 12, 2016

Showing 1-12 of 14

Last Updated: 09/26/2026